We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 10, 2021

Alpelisib + Fulvestrant vs Real-World Standard Treatment in Patients With HR+, HER2−, PIK3CA-Mutated Breast Cancer

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Effectiveness of Alpelisib + Fulvestrant Compared With Real-World Standard Treatment Among Patients With HR+, HER2−, PIK3CA-Mutated Breast Cancer
Oncologist 2021 Apr 28;[EPub Ahead of Print], S Turner, S Chia, H Kanakamedala, WC Hsu, J Park, D Chandiwana, A Ridolfi, CL Yu, JP Zarate, HS Rugo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading